St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the CE Mark approval and European launch of its Prodigy ™ Chronic Pain System with Burst Technology. As the first and only implantable neuromodulation system that delivers burst stimulation, the Prodigy system is designed to reduce pain, improve patient satisfaction and allow reduced paresthesia (a tingling sensation associated with stimulation). The new device offers patients traditional tonic spinal cord stimulation (SCS) in addition to Burst Technology for improved stimulation options.
“Burst Technology expands treatment options for patients suffering from chronic pain and provides significant relief so they can reclaim their quality of life,” said Dr. Dirk De Ridder, Neurological Professor of Neurosurgery, from the University of Otago in Dunedin, New Zealand. “Prodigy’s pioneering stimulation mode allows me to tune therapy to my patient’s unique pain condition. Burst holds promise to fill the void where alternative stimulation modes fail to control patients’ pain or for those who lose therapeutic benefit over time.”
SCS (also known as neurostimulation) therapy uses an implanted device, similar to a cardiac pacemaker, and thin wires with electrodes to deliver low levels of electrical energy to nerve fibers. These electrical pulses mask or interrupt pain signals as they travel to the brain, reducing painful sensations. Traditional stimulation uses equally spaced electrical pulses to replace pain with a tingling sensation called paresthesia. For some patients, the stimulation sensation can fluctuate and paresthesia may become uncomfortable. For others, traditional stimulation does not effectively relieve their pain.
St. Jude Medical’s new Burst Technology offers intermittent “bursts” of stimulation designed to provide an alternative therapy method for chronic conditions such as back pain. In addition, burst stimulation has been demonstrated to minimize paresthesia in some patients which can often fluctuate with posture and body position changes. Early evidence suggests that by enabling the delivery of both modes of stimulation, clinicians can more effectively adjust therapy to address the patient’s unique pain condition.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts